[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[S. 2512 Engrossed in Senate (ES)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
114th CONGRESS
  2d Session
                                S. 2512

_______________________________________________________________________

                                 AN ACT


 
To expand the tropical disease product priority review voucher program 
                to encourage treatments for Zika virus.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Adding Zika Virus to the FDA 
Priority Review Voucher Program Act''.

SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER 
              PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

    Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360n(a)(3)) is amended--
            (1) by redesignating subparagraph (R) as subparagraph (S);
            (2) in subparagraph (Q), by striking ``Filoviruses'' and 
        inserting ``Filovirus Diseases''; and
            (3) by inserting after subparagraph (Q) the following:
                    ``(R) Zika Virus Disease.''.

            Passed the Senate March 17, 2016.

            Attest:

                                                             Secretary.
114th CONGRESS

  2d Session

                                S. 2512

_______________________________________________________________________

                                 AN ACT

To expand the tropical disease product priority review voucher program 
                to encourage treatments for Zika virus.